METHYLPREDNISOLONE INFUSION DURING ACUTE EXACERBATION OF MS - PLASMA AND CSF CONCENTRATIONS

被引：30

作者：

DEFER, DL ^{[1
]}

BARRE, J ^{[1
]}

LEDUDAL, P ^{[1
]}

TILLEMENT, JP ^{[1
]}

DEGOS, JD ^{[1
]}

机构：

[1] UNIV CRETEIL PHARMACOL, CTR HOSP INTERCOMMUNAL, HOSP LAB, CRETEIL, FRANCE

来源：

EUROPEAN NEUROLOGY | 1995年 / 35卷 / 03期

关键词：

MULTIPLE SCLEROSIS; METHYLPREDNISOLONE; PHARMACOKINETICS; CEREBROSPINAL FLUID;

D O I：

10.1159/000117110

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Plasma and CSF concentrations of methylprednisolone (MP), after a high-dose intravenous administration (1,500 mg) prescribed to patients presenting acute exacerbation of multiple sclerosis, were measured. A plasma pharmacokinetic study with 1 CSF sample was performed in 9 patients and 4 other patients had a single plasma sample at the time of lumbar puncture. MP plasma kinetics were similar between patients. Pharmacokinetic parameters were very close to previous published values obtained in normal volunteers or patients with rheumatoid disease. Passage of MP into the CSF was delayed since mean plasma/CSF ratio dropped dramatically from 150 at the 2nd h to 25 at the 3rd h after starting infusion. CSF concentrations of MP were high with a mean reaching 522 mu g/l at the 6th h. The high levels of CSF concentrations suggest that MP may have powerful pharmacological effects within the CNS. No correlation was found between CSF concentration and the clinical response to steroid therapy. The issues related to previous data on clinical, biological and radiological effects of high-dose intravenous MP are discussed in the light of our results.

引用

页码：143 / 148

页数：6

共 31 条

[1] Barnes M.P., Bateman D.E., Cleland P.G., Dick D.J., Walls T.J., Newman P.K., Intravenous meth- ylprednisolone for multiple sclerosis, J Neurol Ncurosurg Psychiatry, 48, pp. 157-159, (1985)
[2] Milligan N.M., Newcombc R., Compston D., A double-blind controlled trial of high-dose methylprcdnisolone in patients wilh multiple sclerosis: 1. Clinical effects, J Neurol Neuro- Surg Psychiatry, 50, pp. 511-516, (1987)
[3] Goodin D.S., The use of immunosuppressive agents in the treatment of multiple sclerosis: A critical review, Neurology, 41, pp. 980-985, (1991)
[4] Compston D.A., Methylprednisolone and multiple sclerosis, Arch Neurol, 45, pp. 669-670, (1988)
[5] Calder V., Owen S., Watson C., Feldmann M., Davison A., MS: A localized immune disease of the central nervous system, Immunol Today, 10, pp. 99-103, (1989)
[6] Hafler D.A., Weiner H.L., MS: A CNS and systemic autoimmune disease, Immunol Today, 10, pp. 104-107, (1989)
[7] Brainin M., Neuhold A., Reisner T., Maida E., Lang S., Deecke L., Changes within the ‘normal’ cerebral white matter of multiple sclerosis patients during acute attacks and during high- dose cortisone therapy assessed by means of quantitative MRI, J Neurol Neurosurg Psychiatry, 52, pp. 1355-1359, (1989)
[8] Burnham J.A., Wright R.R., Dreisbach J., Murray R.S., The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinat- ing lesions, Neurology, 41, pp. 1349-1354, (1991)
[9] Derendorf H., Mollmann H., Rohdewald P., Rehder J., Schmidt E.W., Kinetics of methylprednisolone and its hemisuccinate ester, Clin Pharmacol Ther, 37, pp. 502-507, (1985)
[10] Hayball P.J., Cosh D.G., Scultz D.W., Thomson P., High dose oral methylprednisolone in patients with rheumatoid arthritis: Pharmacokinetics and clinical response, Eur J Clin Pharmacol, 42, pp. 85-88, (1992)

← 1 2 3 4 →